427 A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced melanoma

Background In the United States, melanoma is the fifth leading cancer in men and the seventh in women. Immunotherapy has improved antitumor activity and survival. Overall response rate (ORR) with single agent PD-1 inhibitor is 35%, and 55% with the combination of PD-1/CTLA-4 inhibitors but with significant grade 3–4 toxicity.1 2 Cabozantinib inhibits multiple receptor tyrosine kinases, including c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), and has been shown to have immunomodulatory effects in vitro and in murine models.3 In addition, c-Met has been found to induce overexpression of PD-L1.4 We hypothesize that combination treatment with these two drugs has the potential to improve response rate in metastatic or recurrent melanoma, without significant regimen-limiting toxicities. Methods This trial in progress is an open-label, single center Phase 1b/2 study of the combination of cabozantinib and pembrolizumab in patients with advanced melanoma. Eligible patients have stage IV or recurrent/medically inoperable melanoma, treatment naive for immunotherapy. Prior BRAF and MEK inhibitor is allowed in metastatic setting. Exclusion criteria includes those with ocular or mucosal melanoma or uncontrolled CNS metastases. The trial is currently recruiting.The phase 1b study is based on a 3+3 design with a fixed dose of pembrolizumab (200 mg IV every 3 weeks) and three dose levels of cabozantinib (40, 20 and 60 mg), administered orally daily. The primary endpoint of the phase 1b study is safety of the combination in metastatic melanoma patients. The phase 2 study will be conducted in two stages to evaluate the preliminary efficacy of combination cabozantinib and pembrolizumab, with up to a total of 44 subjects. The study will be terminated early if five or fewer subjects respond in the first stage; otherwise, additional subjects will be accrued. The primary endpoint is best ORR. The secondary endpoints are disease control rate (DCR), duration of DCR, time to response, progression-free survival and overall survival. Exploratory endpoints include assessing biomarkers as a measure of clinical efficacy. Results N/A Conclusions N/A Trial Registration NCT03957551 Ethics Approval The study was approved by The University of Iowa’s Institutional Review Board, approval number 201904712. References Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology 2016;17:1558–68. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature reviews Clinical oncology 2016;13:473–86. Ilangumaran S, Villalobos-Hernandez A, Bobbala D, Ramanathan S. The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions. Cytokine 2016;82:125–39. Balan M, Mier y Teran E, Waaga-Gasser AM, et al. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. The Journal of biological chemistry 2015;290:8110–20.